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Abstract
Background: Hepatocellular carcinoma (HCC) is a malignant cancer with an observable heterogeneity and
microRNAs are functionally associated with the tumorigenesis of HCC. We recently identified that EpCAM (CD326)-
positive cells isolated from alpha-fetoprotein (AFP)-positive HCC samples are hepatic cancer stem cells (HepCSCs).
EpCAM
+AFP
+ HepCSCs have an activated Wnt/b-catenin signaling with a parallel increased expression of all four
microRNA-181 family members. We hypothesized that Wnt/b-catenin signaling transcriptionally activates microRNA-
181s in HCC.
Results: Using both western blot and quantitative reverse transcriptase-PCR analyses, we found that the expression
of all four microRNA-181 family members was positively correlated with b-catenin expression in HCC cell lines.
MicroRNA-181 expression could be directly induced upon an activation of Wnt/b-catenin signaling, which includes
Wnt10B overexpression, inhibition of GSK3b signaling by LiCl, or forced expression of b-catenin/Tcf4. Moreover,
microRNA-181 expression was inhibited upon an inactivation of Wnt/b-catenin signaling by an induction of
adenomatosis polyposis coli (APC) expression or silencing b-catenin via RNA interference. In addition, seven
putative b-catenin/Tcf4 binding sites were identified in the promoter region of the microRNA-181a-2 and
microRNA-181b-2 transcripts. Consistently, we found that Tcf4 interacted with these regions in vivo using
chromatin immunoprecipitation assay.
Conclusions: Taken together, our results demonstrate that microRNA-181s are transcriptionally activated by the
Wnt/beta-catenin signaling pathway in HCC.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignant cancer and the third leading cause of
cancer death worldwide with the observable heterogeneity
in its morphology, clinical behaviour, and molecular pro-
files [1]. Studies on HCC molecular profiling have revealed
many HCC-associated deregulated genes and signaling
pathways, in which Wnt/b-catenin signaling has been pro-
posed to be critical [2-9]. We recently found that isolated
HCC cells using a cell surface marker EpCAM (CD326)
from alpha-fetoprotein (AFP) positive HCC cases are
hepatic cancer stem cells (HepCSCs), where an activation
of Wnt/b-catenin signaling is a major feature [5].
MicroRNAs (miRNAs, miRs) are a class of small, non-
coding, endogenous and functional RNAs. Mature
miRNAs are generated from sequential processing of
primary miRNA transcripts by Drosha and Dicer, then
serve as posttranscriptional regulators of gene expres-
sion in certain biological events including carcinogenesis
[10]. Interestingly, many miRNAs exist as a multi-mem-
ber family indicating their functional redundancy. We
recently found that the miR-181 family contains four
highly conserved mature miR-181s, i.e., miR-181a, miR-
181b, miR-181c and miR-181d, which are derived
independently from 6 precursors located on 3 different
chromosomes. They are miR-181a-1 and miR-181b-1
located on chromosome 1, miR-181a-2 and miR-181b-2
on chromosome 9, and miR-181c and miR-181d on
chromosome 19. We also found that all of these micro-
R N A sa r eh i g h l ye x p r e s s e di nE p C A M
+AFP
+ HepCSCs
[9,10]. In addition, we demonstrate that this family is
critical in maintaining stemness of EpCAM
+AFP
+
HepCSCs, in part by directly targeting an inhibitor of
Wnt/b-catenin signaling (nemo-like kinase [NLK]) and
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i.e., caudal type homeobox transcription factor 2
(CDX2) and GATA binding protein 6 (GATA6). We
also found that inhibition of miR-181s leads to a reduc-
tion in quantity and tumor initiating ability of EpCAM
+AFP
+ HepCSCs, suggesting the potential utility of these
miRNAs as molecular targets of HepCSC [9,10]. The
fact that all four independently encoded miR-181 tran-
scripts are similarly activated to maintain “stemness” is
intriguing, which implies that a common cellular signal-
ing pathway may converge to activate miR-181s. In this
study, we identified that Wnt/b-catenin signaling
appears to be a common activator to induce miR-181s.
Results
Association of miR-181 expression with Wnt/b-catenin
signaling activation
To test whether miR-181s were transcriptional targets of
Wnt/b-catenin, we first examined the expression of
b-catenin and miR-181s in five different HCC cell lines.
Figure 1A and 1B showed that b-catenin and miR-181s
were concordantly expressed in these cell lines. More-
over, we tested the association of miR-181 and b-catenin
using Klotho mice where loss of Klotho, a secreted Wnt
antagonist, leads to b-catenin activation [11]. Consis-
tently, levels of all 4 mature miR-181s in the liver tissues
of Klotho mice were higher than those of wild-type mice
(figure 1C). Therefore, both in vivo and in vitro data
demonstrate that the expression of miR-181s is posi-
tively correlated with the Wnt/b-catenin signaling
pathway.
Wnt/b-catenin signaling activation induces the expression
of all 4 mature miR-181s
To examine whether Wnt/b-catenin signaling could
directly induce miR-181 expression, we first used HuH7
cells with stable WNT10B expression (HuH7 WNT10B
R8) [12]. Compared to control HuH7 cells, HuH7
WNT10B R8 had 6.2-, 4.1-, 8.5-, and 4.4- fold higher
levels of miR-181a, miR-181b, miR-181c and miR-181d,
respectively (figure 2A). Moreover, conditioned media
derived from HuH7 WNT10B R8 also significantly
induced the expression of miR-181s in HuH7 cells
(figure 2A). Second, lithium chloride (LiCl), an activator
of the Wnt/b-catenin pathway through inhibiting glyco-
gen synthase kinase (GSK)-3b then consequently stabi-
lizing b-catenin [13], was applied to further examine the
role of Wnt/b-catenin pathway in regulating miR-181s.
We found that LiCl significantly induced expression of
all 4 miR-181 transcripts in HuH7 (figure 2B) and HuH1
cells (data not shown) when compared to NaCl control
treated cells. Additionally, miR-181s were significantly
induced by ectopic expression of a constitutively acti-
vated b-catenin or a wild type Tcf4, a co-transcriptional
activator of b-catenin, in HuH7 (figure 2C) and HuH1
cells (data not shown). As a control, a dominant negative
T c f - 4m u t a n tf a i l e dt od os o .T h e s ed a t ai n d i c a t et h a t
Wnt/b-catenin signaling activation directly induces
miR-181 expression.
Wnt/b-catenin signaling inhibition reduces the levels of
miR-181s
Several known proteins such as adenomatosis polyposis
coli (APC) can promote b-catenin degradation [14]. To
investigate the effect of Wnt/b-catenin inactivation on the
expression of miR-181s, we used HT29-APC cells where
the APC gene is under the control of a zinc-activated
metallothionein promoter [14]. The levels of all four
miR-181s were significantly decreased in HT29-APC cells
following addition of zinc chloride (ZnCl2), but not in con-
trol HT29-GAL cells (figure 3A). Furthermore, b-catenin
siRNA was employed to suppress Wnt/b-catenin activity
in HuH1 and HuH7 cells. Consistently, declined b-catenin
expression by siRNA (Figure 3B and 3C) significantly
reduced the expression of all four miR-181 transcripts
(figure 3D). These data demonstrate that an inactivation
of Wnt/b-catenin signaling results in an inhibition of miR-
181 expression.
Tcf4 binds to the promoter of miR-181a-2/miR-181b-2
transcript
Studies have shown that the b-catenin/Tcf complex tran-
scriptionally regulates their target gene expression
through binding to a consensus core TCF/LEF-binding
site (5’-A/T A/T CAAAG-3’) within the promoter
regions [15,16]. GenBank database analyses indicate that
miR-181a-1 and miR-181b-1 are located in the intron 2
of a novel host gene (RP11-31E23.1-001) on 1q31 (data
not shown), while miR-181a-2 and miR-181b-2 are
located in the intron 2 of a novel transcript, RP11-
348K2.1-001, on 9q33 (figure 4A). We searched the core
TCF/LEF binding site within 4kb genomic sequences of
the predicted promoter regions of these two genes. Seven
TCF/LEF binding elements were identified in the promo-
ter region of RP11-348K2.1-001 (figure 4A), and three
elements were in the promoter region of RP11-31E23.1-
001 (data not shown). MiR-181c and miR-181d are
present in the intergenic region of chromosome 19 and
consequently no promoter region is available for analysis.
Furthermore, RP11-348K2.1-001 was selected for chro-
matin immuoprecipitation (ChIP) assay using Tcf4 anti-
body in Hep3B cells where both b-catenin and miR-181s
are highly elevated. We designed two amplicons within a
200-bp window, i.e., amplicon U (in the upstream of
transcription site) and amplicon D (in the downstream of
transcription site) (figure 4B). The results showed that
Tcf4 specifically bound to both amplicons in the miR-
181a-2/miR-181b-2 promoter (figure 4C), indicating that
Ji et al. Cell & Bioscience 2011, 1:4
http://www.cellandbioscience.com/content/1/1/4
Page 2 of 8Hep3B
HuH7
HuH1
MHCC97
Smmc7721
0
10
20
30
miR-181a
miR-181b
miR-181c
miR-181d
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
(
/
H
e
p
a
t
o
c
y
t
e
s
)
A.
C.
β-catenin
β-actin
Hep3B
HuH7
HuH1
MHCC97
Smmc7721
1.00 0.51 0.53 0.37 0.38
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
B.
miR-181a
WT
Klotho KO
-0.6
-0.3
0.0
0.3
0.6
0.9
1.2
miR-181b
WT
Klotho KO
miR-181c
WT
Klotho KO
miR-181d
WT
Klotho KO
Figure 1 Expression of miR-181 is associated with b-catenin level. (A) Western blot analysis of b-catenin and b-actin in Hep3B, HuH7, HuH1,
MHCC97 and Smmc7721 HCC cell lines. The relative intensity of b-catenin was listed on the top of individual western blot band. (B) qRT-PCR
analysis of the four mature miR-181s in five HCC cell lines. Levels of miR-181s in these HCC cell lines were measured in triplicate and normalized
by U6 level. After further normalization by the reading in adult primary human hepatocytes, the relative level for each miRNA was shown as the
mean ± standard deviation. (C) qRT-PCR analysis of the four mature miR-181s in liver tissues from three wild-type mice and two Klotho knockout
mice. miR-181s’ level in these tissues was measured in triplicate, normalized to levels of U6.
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Figure 2 Wnt/b-catenin signaling activation induces the level of miR-181. (A) qRT-PCR analysis of all four mature miR-181s in HuH7 and
HuH7 WNT10B R8 cells (left panel) and in HuH7 cells cultured with normal media or conditioned media from HuH7 WNT10B R8 for 3 days (right
panel). (B) qRT-PCR of miR-181s in HuH1 and HuH7 cells incubated with LiCl or NaCl for 3 days. (C) qRT-PCR analysis of all four mature miR-181s
in HuH7 cells and HuH1 cells with transient transfection of b-catenin, wild-type Tcf4 (wt-Tcf4), dominant negative Tcf4 (dn-Tcf4) or control for
three days. The experiments were performed in triplicates and results were shown as mean ± standard deviation. * refers to p < 0.05.
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Figure 3 Wnt/b-catenin signaling inhibition reduces the expression of miR-181. (A) HT29-APC and HT29-GAL cells were incubated with
100 μM of ZnCL2 for different time points (0 hours, 24 hours and 48 hours). Then qRT-PCR analysis of all four mature miR-181s was performed
in these cells. (B, C) b-catenin siRNA and control siRNA was transfected in HuH7 and HuH1 cells using lipofectamine 2000. Western blotting
analysis of b-catenin and b-actin (left panel) and qRT-PCR analysis of CTNNB1 (right panel) were performed (B). qRT-PCR analysis of all four
mature miR-181s (C). All these experiments were done in triplicates and the level of miRNAs and genes were shown as mean ± standard
deviation. * refers to p < 0.05.
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scriptional target of Wnt/b-catenin canonical signaling
pathway in HCC.
Discussion
HCC is an aggressive cancer with extensive clinical and
g e n o m i ch e t e r o g e n e i t y .W eh a v ep r e v i o u s l yu t i l i z e da
combination of EpCAM and AFP expression to identify
two distinct HCC subgroups, i.e., EpCAM
+AFP
+ HCCs
(named as HpSC-HCCs) with poor prognosis, high
metastasis, and the presence of a hepatic stem cell
(HpSC) feature, and EpCAM
-AFP
- HCCs (named as
MH-HCCs) with good prognosis and the presence of a
mature hepatocytes (MH) feature. We have experimen-
tally demonstrated that EpCAM
+AFP
+ HCC cells are
HepCSCs [3,5,15]. Interestingly, cDNA and microRNA
array analyses indicate that Wnt/b-catenin signaling is
activated and all four miR-181 family members are
highly expressed in both HpSC-HCC clinical specimens
and in isolated HepCSCs [5,9]. These results suggest
that Wnt/b-catenin might be a key regulator of miR-
181. The exploration of the molecular link between
Wnt/b-catenin and miR-181 would further increase our
understanding of the intricate molecular regulation in
cancer stem cells and facilitate the designing of effective
strategies to eliminate cancer stem cells, which are
thought to be responsible for tumour relapse and drug
resistance.
Our current study has demonstrated that the Wnt/b-
catenin signaling pathway can directly regulate miR-181s
expression in HCC. This conclusion is based on the fol-
lowing observations: 1) miR-181 expression was posi-
tively associated with b-catenin level in both HCC cell
lines and mouse livers where b-catenin is augmented; 2)
activation of Wnt/b-catenin signaling directly induced
miR-181 expression, while inhibition of Wnt pathway
directly reduced miR-181 expression; 3) we found evi-
dence of in vivo binding between the Tcf4/b-catenin
complex and the TCF/LEF binding elements in the pro-
moter region of miR-181a-2/miR-181b-2 transcript.
Wnt/b-catenin is a key molecular signaling regulator
in embryonic stem cells and in a variety of human can-
cers including HCC. Similarly, Wnt/b-catenin signaling
i sk n o w nt ob ei n v o l v e di nl i v e rd e v e l o p m e n ta n d
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Figure 4 Tcf4 associates with the promoter of miR-181s. (A) Predicted Tcf4 binding sites in the promoter region of the miR-181a-2/miR-
181b-2 gene. (B) PCR amplicons for ChIP assay were designed within 200-bp windows in the ~700-bp upstream of the transcription start site
(amplicon U), and in the ~500-bp downstream of transcription start site (amplicon D). (C) PCR analysis of Tcf4 chromatin immunoprecipitate.
Actin chromatin immunoprecipitate was used as negative control. PCR products were run on a 3.0% agarose gel.
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Page 6 of 8regeneration, and has been shown to be activated in
EpCAM
+ HepCSCs [5,17-19]. Interestingly, miR-181s
maintain the stemness of HepCSCs partially through
suppressing NLK, an inhibitor of Wnt/b-catenin signal-
ing, to consequently induce the transcriptional activity
of Tcf4/b-catenin [10]. Our findings revealed a positive
feedback regulatory loop between miR-181 and Wnt/b-
catenin signaling in maintaining stemness of HepCSCs
where either miR-181s or Wnt/b-catenin can promote
stemness by targeting the pool of their downstream
genes. A future challenge will be to explore this positive
feedback loop as a molecular target to eradicate hepatic
cancer stem cells.
Conclusions
The Wnt/beta-catenin signaling is a major transcrip-
tional regulator of miR-181s expression.
Methods
Plasmids, small interfering RNAs (siRNAs), antibodies and
chemicals
Constitutively active b-catenin expression vector (pCI-
NEO-bcateninXL) (mutated at S33Y), wild-type Tcf4
expression vector (pcDNA/myc-hTcf4) and dominant
negative Tcf4 expression vector (pcDNA/myc-ΔN-
hTcf4) were generous gifts from Dr. Bert Vogelstein
[20]. b-catenin siRNA and negative control siRNA were
purchased from Qiagen. Anti-b-catenin monoclonal
antibody (BD Transduction Laboratories), anti-b-actin
monoclonal antibody (Sigma) and anti-Tcf-4 monoclo-
nal antibody (Chemicon) were used in this study.
Lithium chloride, sodium chloride and zinc chloride
were commercially available (Sigma).
Cells, conditioned medium, transfection and mice liver
tissues
Human HCC cell lines (Hep3B, HuH7, HuH1, MHCC97
and Smmc7721) were cultured as previously described
[6]. HT29-APC, HT29-GAL cells were kindly provided
by Dr. Bert Vogelstein and routinely cultured as
described [14,15]. To induce APC’s expression, we incu-
bated HT29-APC cells with 100 μmol/L of zinc chloride
for 24 and 48 hours. HuH7 cells with stably expressed
WNT10B (WNT10B clone R8) were maintained in our
lab [12]. WNT10B conditioned media were prepared
from HuH7 WNT10B R8. Three wild-type and two
Klotho knock out mice were kindly given by Dr. Toren
Finkel. Liver tissues were dissected from these mice and
immediately stored at -80°C until RNA extraction.
Transfection of siRNAs and plasmids was done using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instrument. A total of 100nM siRNAs or 2 μg/
ml plasmids were used for each transfection. Total RNA
was extracted three days after transfection.
RNA extraction and quantitative real-time reverse
transcription PCR (qRT-PCR)
Total RNA was extracted using Trizol (Invitrogen).
Reverse transcription was done using High Capacity
cDNA Reverse Transcription Kit for mRNAs and Taq-
Man MicroRNA Reverse Transcription Kit for miRNAs.
The expression of mRNAs and mature miRNAs was
measured using Taqman Gene Assay specific for
CTNNB1 and Taqman MicroRNA Assays specific for
miR-181a, miR-181b, miR-181c and miR-181d (Applied
biosystems). The experiments were performed in tripli-
cate. The Taqman gene assay for 18S and Taqman
MicroRNA Assay for U6 RNA were used to normalize
the relative abundance of mRNA and miRNA,
respectively.
Protein extraction and western blotting
Total protein was extracted as previously described [6].
They were electrophoresed on 10% Tris-Glycine Gel
(Invitrogen) and transferred to nitrocellulose membrane
(Invitrogen). The membrane was incubated with anti-b-
catenin and anti-b-actin, followed by anti-mouse IgG
conjugated to horseradish peroxidase. The bands were
developed using enhanced chemiluminescence detection
reagents (Amersham).
Chromatin immuoprecipitation (ChIP)
ChIP assay was done using the Chromatin Immunopre-
cipitation Assay Kit (Upstate), Hep3B cells and anti-Tcf4
antibody according to the manufactures’ instrument.
The oligonucleotides flanking transcription start site and
predicted Tcf4 binding sites were designed within
~200-bp windows in the 700-bp upstream of the tran-
scription start site (amplicon U), and in the 500-bp win-
dows downstream of transcription start site (amplicon D)
for detecting miR-181a-2 and miR-181b-2 promoter. The
primers were 5’-aaa caa agc aac tgc cat gta ct-3’ (sense)
and 5’-agg gtc ctt ggg gtt tat ttt-3’ (antisense) for ampli-
con U, and 5’-ggt tgc ttt cca ttc ttt gc-3’ (sense) and 5’-ttt
ggc cac aca aaa cta gag at-3’ (antisense) for amplicon D.
The PCR was done using Platinum Taq Polymerase High
Fidelity (Invitrogen).
Statistical analyses
Student’s t-test (two-tailed) was used for statistical ana-
lysis of comparative data between different groups. p <
0.05 was considered to be statistically significant. Data
were presented as the mean ± standard deviation (S.D.)
and the analyses were performed using GraphPad Prism
software 5.0 (GraphPad Software, San Diego, CA).
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